Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
204 studies found for:    "Eye Diseases, Hereditary" OR "Peters plus syndrome"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Active, not recruiting Efficacy and Safety of Oral Valproic Acid for Retinitis Pigmentosa
Conditions: Retinitis Pigmentosa;   Retinal Diseases;   Eye Diseases;   Eye Disease, Hereditary;   Retinal Degeneration
Intervention: Drug: Valproic Acid
2 Completed Fundus Changes in the Microphthalmy Eyes
Condition: Eye Diseases, Hereditary
Intervention:
3 Completed Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy
Conditions: Graves Ophthalmopathy;   Graves Disease;   Eye Diseases;   Thyroid Diseases;   Endocrine System Diseases;   Eye Diseases, Hereditary;   Hyperthyroidism;   Autoimmune Diseases;   Immune System Diseases
Intervention: Drug: Doxycycline
4 Recruiting Doxycycline Treatment in Mild Graves' Orbitopathy
Conditions: Graves Ophthalmopathy;   Graves Disease;   Eye Diseases;   Thyroid Diseases;   Endocrine System Diseases;   Eye Diseases, Hereditary;   Hyperthyroidism;   Autoimmune Diseases;   Immune System Diseases
Interventions: Drug: Doxycycline;   Drug: placebo
5 Completed Screening for Studies on Inherited Eye Diseases
Condition: Hereditary Eye Disease
Intervention:
6 Completed Evaluation and Treatment of Patients With Inherited Eye Diseases
Condition: Hereditary Eye Disease
Intervention:
7 Withdrawn Intravitreal Bevacizumab vs.Combination Therapy for CNV Due to Other Than AMD
Conditions: Choroidal Neovascularization;   Myopia;   Punctate Inner Choroidopathy (PIC);   Multifocal Choroiditis;   Ocular Histoplasmosis Syndrome;   Central Serous Chorioretinopathy (CSC);   Angioid Streaks;   Trauma, or Hereditary Eye Diseases
Interventions: Drug: Bevacizumab (Avastin; Genentech, Inc.);   Drug: Bevacizumab, Dexamethasone, Verteporfin Photodynamic Therapy
8 Recruiting Congenital Muscle Disease Study of Patient and Family Reported Medical Information
Conditions: Muscular Dystrophy;   Congenital Muscular Dystrophy;   Fukutin-related Protein Gene;   Limb Girdle;   FKRP Gene;   Childhood Onset LGMD;   Adult Onset LGMD;   POMT1;   POMT2;   POMGnT1;   LARGE;   Alpha Dystroglycan;   Dystroglycanopathy;   Centronuclear;   Multiminicore;   Multicore;   Minicore;   Congenital Fiber Type Disproportion;   Myotubular;   Nemaline;   Congenital Myopathy;   Neuromuscular;   Rigid Spine;   Phenotype-Genotype Correlation;   Cough Assisted Device;   Neuromuscular Disease;   Respiratory Exacerbation;   Invasive Ventilation;   Chest Physiotherapy;   Congenital Myopathies;   Genetic Mutations;   Hypertrophic Cardiomyopathy;   Wheelchair Use;   Cataract;   Opthalmoplegia;   Ullrich Congenital Muscular Dystrophy;   Intermediate Collagen VI Myopathy;   Laminin Alpha 2 Related Congenital Muscular Dystrophy;   MDC1A;   Merosin Deficient Congenital Muscular Dystrophy;   Congenital Muscular Dystrophy Undiagnosed;   Congenital Muscular Dystrophy Merosin Positive;   Walker Warburg Syndrome;   Muscle Eye Brain Disease;   Fukuyama;   Integrin Alpha 7 Deficiency;   Integrin Alpha 9 Deficiency;   Laminopathy;   Lamin AC;   SEPN 1 Related Myopathies;   Bethlem Myopathy;   Dystroglycanopathies;   LGMD2K;   LGMD2I;   LGMD2L;   LGMD2N;   Actin Aggregation Myopathy;   Cap Disease;   Central Core Disease;   Centronuclear Myopathy;   Core Rod Myopathy;   Hyaline Body Myopathy;   Multiminicore Myopathy;   Myotubular Myopathy;   Nemaline Myopathy;   Tubular Aggregate Myopathy;   Zebra Body Disease Myopathy;   Congenital Myopathy Other;   Reducing Body Myopathy;   Sarcotubular Myopathy;   Spheroid Body Myopathy
Intervention:
9 Recruiting Safety and Efficacy of Subretinal Implants for Partial Restoration of Vision in Blind Patients
Conditions: Retinitis Pigmentosa;   Retinal Degeneration
Intervention: Device: Device name: "Retina Implant model Alpha". Surgical implantation of medical device into eye
10 Completed Treatment of Congenital Stationary Night Blindness With an Alga Containing High Dose of Beta Carotene
Condition: Night Blindness
Intervention: Dietary Supplement: alga Dunaliella bardawil
11 Recruiting Screening Protocol for Genetic Diseases of Mast Cell Homeostasis and Activation
Conditions: Piebaldism;   Idiopathic Anaphylaxis;   Allergy;   Chronic Urticara;   Angioedema
Intervention:
12 Recruiting Natural History and Genetic Studies of Usher Syndrome
Conditions: Retinitis Pigmentosa Syndromic;   Congenital Deafness;   Usher Syndrome;   Retinitis Pigmentosa and Deafness;   Progressive Hearing Loss;   Retinitis Pigmentosa
Intervention:
13 Recruiting Selenium in Mild Thyroid Eye Disease in North America
Condition: Thyroid Associated Ophthalmopathies
Interventions: Dietary Supplement: Sodium selenite;   Dietary Supplement: Sugar pill
14 Recruiting Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease
Condition: Thyroid Eye Disease
Interventions: Drug: Hyaluronic Acid Gel injection;   Drug: Saline injection
15 Completed Leber Hereditary Optic Neuropathy (LHON) Historical Case Record Survey
Condition: Leber Hereditary Optic Neuropathy (LHON)
Intervention:
16 Active, not recruiting TES for the Treatment of RP
Condition: Retinitis Pigmentosa
Intervention: Device: Transcorneal electrical stimulation
17 Completed Evaluation of Safety of Ciliary Neurotrophic Factor Implants in the Eye
Condition: Retinitis Pigmentosa
Intervention: Drug: Ciliary Neurotrophic Factor Implant NT-501
18 Completed Umbilical Cord Blood Mononuclear Cell Transplant to Treat Chronic Spinal Cord Injury
Condition: Spinal Cord Injuries
Interventions: Biological: Umbilical Cord Blood Mononuclear Cell;   Biological: Methylprednisolone;   Drug: Lithium Carbonate Tablet
19 Recruiting Safety Study of an Adeno-associated Virus Vector for Gene Therapy of Leber's Hereditary Optic Neuropathy (LHON) Caused by the G11778A Mutation
Conditions: Leber's Hereditary Optic Neuropathy;   G11778A Gene Mutation;   Human Mitochondrial ND4 Gene
Interventions: Drug: scAAV2-P1ND4v2 5.00x10e9 vg (Low),;   Drug: scAAV2-P1ND4v2 2.46X10e10 vg (Med);   Drug: scAAV2-P1ND4v2 1.0X10e11vg (High)
20 Unknown  IRIS PILOT - Extended Pilot Study With a Retinal Implant System
Conditions: Retinitis Pigmentosa;   Cone-Rod Dystrophy;   Choroideremia
Intervention: Device: Retinal Implant System (IRIS)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years